Cystic fibrosis pancreatic enzyme replacement

Pancreatic enzyme replacement or supplement when enzymes are absent or deficient, such as with chronic pancreatitis, cystic fibrosis, or ductal obstruction from cancer of the pancreas or common bile duct to reduce malabsorption treatment of steatorrhea associated with bowel resection or postgastrectomy syndrome PO 1-3 capsules ortablets before or with meals or snacks. May increase to 8 tablets/dose. 

Pancrelipase Replacement enzymes from animal pancreatic extracts Improves digestion of dietary fat, protein, and carbohydrate Pancreatic insufficiency due to cystic fibrosis, pancreatitis, pancreatectomy Taken with every meal may increase incidence of gout... 

H. Heijerman, C. Lamers, J. Dijkman, and W. Bakker. Ranitidine compared with the dimethylprostaglandin E2-analogue enprostil as adjunct to pancreatic enzyme replacement in adult cystic fibrosis. Scand. J. Gastroenterol. 25(suppl 178) 26 (1990). 

G. Cleghom, R. Shepherd, and T. Holt. The use of a synthetic prostaglandin Ei analogue (Misoprostol) as an adjunct to pancreatic enzyme replacement in cystic fibrosis. Scand. J. Gastmenteml. 23(suppl 143) 142 (1988). 

David V, Kapel N, Dyard F, Henniges F. Pancreatic enzyme replacement therapy for young cystic fibrosis patients. J Cyst Fibres 2009 8 14-8. 

These drug are prescribed as replacement therapy for those with pancreatic enzyme insufficiency. Conditions or diseases that may cause a decrease in or absence of pancreatic digestive enzymes include cystic fibrosis, chronic pancreatitis, cancer of the pancreas,... 

Enzyme replacement therapy (ERT) is a therapeutic approach in which the specific enzyme that is absent or inactive in affected individuals is replaced with a functional enzyme molecule. Pancreatic enzyme preparations of porcine or bovine origin have been available in the United States for treatment of exocrine pancreatic insufficiency (EPI) in children and adults with cystic fibrosis and chronic pancreatitis since before the enactment of the Federal Food, Drug and Cosmetic Act of 1938 (ref FDA guidance on EIP April 2004). A... 

Figure 48-8 Fecal excretion (mean and SD) of chymotrypsin, fat, and immunoreactive elastase during a 24-hour collection period in 12 patients with cystic fibrosis and steatorrhea with and without enzyme replacement therapy. (From Stein JJung M, Sziegoleit A, Zeuzem S, Caspary WF, Lembcke B. immunoreactive elastase / c//njco/ eva/uat/on of a new non-invasive test of pancreatic function, din Cbem 1996 42 222 6.)...

---